Literature DB >> 33604211

Fentanyl Infusion Is Effective in the Treatment of Dyspnea in End-Stage Heart Failure With Renal Failure: A Case Report.

Ryo Sakamoto1, Atsuko Koyama1.   

Abstract

Patients with end-stage heart failure may require hospitalization for the treatment of respiratory distress. Morphine may be used to relieve symptoms. However, use of morphine is problematic because heart failure is often associated with renal dysfunction. In this case report, intravenous fentanyl infusion reduced dyspnea in a patient with end-stage heart failure who was on dialysis induction to treat renal failure. The patient was able to eat and sleep after administration of an intravenous fentanyl solution and experienced no apparent respiratory depression as a side effect of fentanyl. There have been few reports of dyspnea relief with fentanyl infusion. Because of its adjustable duration of effect, intravenous fentanyl may be a more effective and useful option than rapid or extended-release agents in cases such as this one.
Copyright © 2021, Sakamoto et al.

Entities:  

Keywords:  dyspnea; end-stage heart failure; fentanyl; palliative care

Year:  2021        PMID: 33604211      PMCID: PMC7880850          DOI: 10.7759/cureus.12673

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  10 in total

Review 1.  Delirium in elderly people.

Authors:  Sharon K Inouye; Rudi G J Westendorp; Jane S Saczynski
Journal:  Lancet       Date:  2013-08-28       Impact factor: 79.321

Review 2.  Fentanyl for the relief of refractory breathlessness: a systematic review.

Authors:  Steffen T Simon; Peyla Köskeroglu; Jan Gaertner; Raymond Voltz
Journal:  J Pain Symptom Manage       Date:  2013-06-04       Impact factor: 3.612

3.  Benzodiazepine Use and Long-Term Mortality in Real-Life Chronic Heart Failure Outpatients: A Cohort Analysis.

Authors:  Crisanto Diez-Quevedo; Josep Lupon; Marta de Antonio; Mar Domingo; Marta Martin-Subero; Teresa Rangil; Pedro Moliner; Elisabet Zamora; Salvador Altimir; Javier Santesmases; Maria Isabel Troya; Maria Boldo; Joan de Pablo; Antoni Bayes-Genis
Journal:  Psychother Psychosom       Date:  2018-10-10       Impact factor: 17.659

4.  The Use of Intranasal Fentanyl for the Palliation of Incident Dyspnea in Advanced Congestive Heart Failure: A Pilot Study.

Authors:  Jana Pilkey; Allison Pedersen; James W Tam; Amrit Malik; Jonathan Wong
Journal:  J Palliat Care       Date:  2018-05-31       Impact factor: 2.250

Review 5.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

6.  Depression, antidepressants, and long-term mortality in heart failure.

Authors:  Crisanto Diez-Quevedo; Josep Lupón; Beatriz González; Agustín Urrutia; Lucía Cano; Roser Cabanes; Salvador Altimir; Ramon Coll; Teresa Pascual; Marta de Antonio; Antoni Bayes-Genis
Journal:  Int J Cardiol       Date:  2012-04-14       Impact factor: 4.164

Review 7.  Palliative Care in Heart Failure.

Authors:  Abhinav Sood; Krista Dobbie; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-19

8.  Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study.

Authors:  David C Currow; Christine McDonald; Sheila Oaten; Bernadette Kenny; Peter Allcroft; Peter Frith; Michael Briffa; Miriam J Johnson; Amy P Abernethy
Journal:  J Pain Symptom Manage       Date:  2011-03-31       Impact factor: 3.612

Review 9.  The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis.

Authors:  Marta M Maslej; Benjamin M Bolker; Marley J Russell; Keifer Eaton; Zachary Durisko; Steven D Hollon; G Marie Swanson; J Anderson Thomson; Benoit H Mulsant; Paul W Andrews
Journal:  Psychother Psychosom       Date:  2017-09-14       Impact factor: 17.659

Review 10.  Prevalence and importance of comorbidities in patients with heart failure.

Authors:  Filippos K Triposkiadis; John Skoularigis
Journal:  Curr Heart Fail Rep       Date:  2012-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.